Reply to S. Zhang, L. Fornaro et al, and H.J. Lee et al

Affiliations

¹ Shukui Qin, People's Liberation Army Cancer Center, Bayi Hospital of People's Liberation Army, Nanjing, People's Republic of China; Jin Li, Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.

Comment

Shukui Qin et al. J Clin Oncol. 2016.

. 2016 Nov 1;34(31):3823-3824.

doi: 10.1200/JCO.2016.69.1071.

¹ Shukui Qin, People's Liberation Army Cancer Center, Bayi Hospital of People's Liberation Army, Nanjing, People's Republic of China; Jin Li, Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.

No abstract available

Comment on

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Li J, et al. J Clin Oncol. 2016 May 1;34(13):1448-54. doi: 10.1200/JCO.2015.63.5995. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884585 Clinical Trial.
Problematic Analysis and Inadequate Toxicity Data in Phase III Apatinib Trial in Gastric Cancer.
Zhang S. Zhang S. J Clin Oncol. 2016 Nov 1;34(31):3821. doi: 10.1200/JCO.2016.67.3889. J Clin Oncol. 2016. PMID: 27528723 Free PMC article. No abstract available.
Is Treatment-Emergent Toxicity a Biomarker of Efficacy of Apatinib in Gastric Cancer?
Lee HJ, Moon JY, Baek SW. Lee HJ, et al. J Clin Oncol. 2016 Nov 1;34(31):3823. doi: 10.1200/JCO.2016.68.8663. J Clin Oncol. 2016. PMID: 27528729 Free PMC article. No abstract available.
Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward.
Fornaro L, Vasile E, Falcone A. Fornaro L, et al. J Clin Oncol. 2016 Nov 1;34(31):3822-3823. doi: 10.1200/JCO.2016.68.6931. J Clin Oncol. 2016. PMID: 27528730 Free PMC article. No abstract available.

1. Zhang S. Problematic analysis and inadequate toxicity data in phase III apatinib trial in gastric cancer. J Clin Oncol. 2016;34:3821. - PMC - PubMed
1. Fornaro L, Vasile E, Falcone A. Apatinib in advanced gastric cancer: A doubtful step forward. J Clin Oncol. 2016;34:3822–3823. - PMC - PubMed
1. Lee HJ, Moon JY, Baek SW. Is treatment-emergent toxicity a biomarker of efficacy of apatinib in gastric cancer? J Clin Oncol. 2016;34:3823. - PMC - PubMed
1. Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448–1454. - PubMed
1. US Food and Drug Administration Guidance for industry: E9 statistical principles for clinical trials. http://purl.access.gpo.gov/GPO/LPS117508.